Wolverine Legal Status: what do FDA records mean?

What does the current Wolverine legal status mean for you?

In 2026, a federal review could have changed pharmacy access. FDA advisers discussed both parts on July 23-24, 2026 ^[13]. They considered whether pharmacies could mix either part for one patient. A discussion alone does not change a rule.

FDA first put both parts on a safety concern list called Category 2. That happened on September 29, 2023. Its current page lists both substances under “Bulk drug substances nominated but withdrawn” ^[12]. FDA has approved neither part or the blend ^[12].

Withdrawal means the requests stopped moving through that review. FDA says the nominators withdrew them; its safety concerns remain beside the entries. Category 1 gave some substances short-term room while under review. Leaving Category 2 did not give these parts that temporary room.

For a clinic or pharmacy, the practical answer is strict. Those withdrawn nominations give no permission to compound either part. The sport rules for tested athletes are separate. A doctor, pharmacy, or lawyer must apply the rule to your case.

The withdrawn nominations are no longer being evaluated for the 503A list. Withdrawal does not give a medicine approval. It also does not give a pharmacy clear permission. The rule in force today controls access.

Can a clinic or pharmacy supply either part?

One federal rule covers medicine mixed for one patient. A doctor writes a prescription, and a state-licensed pharmacy makes it ^[12]. Larger batches follow a second federal rule ^[12]. Each rule has its own safety and production terms.

FDA once sorted pending requests into two groups. Category 1 gave pharmacies some room while a substance was reviewed. Category 2 marked possible major safety risks ^[12]. Leaving Category 2 ended the request but did not grant approval.

The BPC-157 request covered two lab forms. “Free base” meant BPC-157 without an added salt. BPC-157 acetate had a small salt part attached. Neither form is an approved medicine.

FDA put the request in Category 2 on September 29, 2023 ^[12]. The agency noted possible immune reactions and unwanted material that is hard to check. Those notes remain beside the withdrawn request. The page does not say the concerns were cleared or newly confirmed.

The TB-500 request concerned one small section of Thymosin Beta-4. FDA put TB-500 in Category 2 on September 29, 2023 ^[12]. The agency noted immune concerns and missing safety facts. Its current TB-500 page still names that Thymosin Beta-4 piece ^[12].

Did the July 2026 federal review change access?

Both parts appeared on the FDA group's July 2026 agenda ^[13]. The group was to weigh pharmacy mixing for one patient. By then, both requests had been withdrawn. FDA staff had advised against adding either part to the allowed list.

As of September 2026, FDA had not posted the members' vote. Staff advice does not make the final rule. FDA must change its list through an official rule ^[12]. The July 2026 meeting alone did not change access.

The firm federal page still marks the requests withdrawn. That means the old listing requests ended. It does not create approval or a clear pharmacy path. A pharmacy must apply the rule now in force.

What has to happen before a pharmacy can mix medicine?

A legally mixed medicine begins with one patient's medical visit. A licensed doctor decides whether that medicine fits the patient. The doctor then writes a prescription for that person ^[12]. A state-licensed pharmacy may prepare it when the ingredient is allowed.

Registered sites can make larger batches under another federal path ^[12]. A phone or video visit can count as the medical visit. It can lead to a prescription when a licensed doctor finds the medicine fits ^[12]. The visit does not change which ingredients are allowed.

For BPC-157 and TB-500, the posted FDA page gives no clear mixing permission. The old safety notes remain beside both withdrawn requests. Withdrawal itself supplies no permission to compound either part ^[12]. For an ordinary patient, a licensed prescriber's assessment comes before any prescription; a withdrawn nomination guarantees neither access nor lawful compounding.

The firm points are simple. Neither part has approval for people. A clinic cannot make federal limits disappear. A doctor and pharmacy must apply the current rules to your case.

Are BPC-157 and TB-500 approved or barred in tested sports?

Neither part has federal approval for people. FDA put both on its Category 2 safety concern list during 2023 ^[12]. The sport testing group called WADA bars BPC-157 and Thymosin Beta-4, including TB-500. For a tested athlete, both remain barred.

Does “Wolverine” have an approved medical use?

Neither part nor the blend has an approved medical purpose ^[12]. FDA lists both substances among the withdrawn nominations. Withdrawal ended those requests. Sport rules still bar both parts in covered events.

What can a pharmacy do with BPC-157 now?

Patient-specific prescribing does not settle the separate rules for compounding BPC-157. BPC-157 entered Category 2 on September 29, 2023. FDA's current table records its nomination as withdrawn ^[12]. A July 23-24, 2026 review did not change the rule by itself ^[13].

What is FDA’s current status for the full Wolverine blend?

FDA put BPC-157 and TB-500 in Category 2 during September 2023. Its current page marks both listing requests withdrawn from Category 2 ^[12]. That ended the old requests but did not approve either part. The July 23-24, 2026 review was one step, not a final decision ^[13].